Von Willebrand Disease Clinical Trial
Official title:
Changes in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle
The primary objective of this study is to describe characteristics and trends for thrombin generation (TG) and thromboelastography (TEG) at 4 time points during the menstrual cycle.
Status | Terminated |
Enrollment | 20 |
Est. completion date | April 2013 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Females of reproductive age with regular menstrual cycles and a diagnosis of von Willebrand disease according to the International Society of Thrombosis and Hemostasis diagnostic criteria. Exclusion Criteria: - Females who are pregnant, or have a history of endocrinopathy or hormone imbalance - History of hysterectomy or bilateral oophorectomy - History of ovarian or uterine cancer - Use of intrauterine device - Use of antifibrinolytic therapy, hemostatic agents, or anti-platelet agents. |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Health Science Center at Houston | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston | The ZLB Behring Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Endogenous Thrombin Potential | Comparison of 4 values collected during 4 phases of through the menstrual cycle | 4 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01651468 -
The Effect of the Nutraceutical "Hemofix" on the Coagulation System
|
N/A | |
Active, not recruiting |
NCT00555555 -
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
|
Phase 4 | |
Completed |
NCT02552576 -
Study of Voncento® in Subjects With Von Willebrand Disease
|
Phase 4 | |
Recruiting |
NCT02869074 -
Molecular and Clinical Profile of Von Willebrand Disease in Spain
|
||
Completed |
NCT01602419 -
Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
|
||
Completed |
NCT01224808 -
Extension Study of Biostate in Subjects With Von Willebrand Disease
|
Phase 3 | |
Completed |
NCT00805051 -
Acquired Von Willebrand Syndrome in Severe Aortic Stenosis
|
N/A | |
Withdrawn |
NCT00694785 -
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
|
Phase 2 | |
Completed |
NCT02246881 -
A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.
|
Phase 3 | |
Completed |
NCT00168090 -
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
|
Phase 4 | |
Completed |
NCT04657887 -
Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
|
||
Withdrawn |
NCT00630448 -
Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)
|
N/A | |
Terminated |
NCT00387192 -
A Study With OPTIVATE® in People With Von Willebrand Disease
|
Phase 3 | |
Completed |
NCT02973087 -
rVWF IN PROPHYLAXIS
|
Phase 3 | |
Completed |
NCT01410227 -
Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
|
Phase 3 | |
Completed |
NCT01949220 -
Willebrand International Non-interventional Global Surveillance
|
||
Completed |
NCT01589848 -
Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador
|
N/A | |
Completed |
NCT00941616 -
Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00557908 -
The Von Willebrand Disease (VWD) International Prophylaxis Study
|
N/A | |
Active, not recruiting |
NCT04953884 -
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease VWD) Patients <6 Years of Age
|
Phase 3 |